The LimFlow System for Transcatheter Arterialization of Deep Veins (TADV) is now the only option other than amputation for ceratin CLTI patients who have lost blood flow below their knee. LimFlow’s TADV system won breakthrough device designation in October 2017 and secured FDA premarket approval (PMA) in September 2023.
“A lot of technologies come out of people fiddling with technologies that already exist, and then developing unique proprietary solutions after that,” LimFlow CEO Dan Rose said in an interview with Medica…